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INTRODUCTION
The active form of vitamin D, 1α,25(OH)2D3 (1,25D) elicits
cellular responses through both genomic and non-genomic
actions (1). Vitamin D has been shown to be important in
phosphate and calcium homeostasis (2) acting on the intestine
(3), kidney (4), parathyroid gland (5) and bone (6). It exerts its
effects through the vitamin D receptor (VDR) and the discovery
of the VDR in muscle tissue (7, 8) suggests that vitamin D will
also act on muscle tissue. Indeed, the deregulated expression of
myoregulatory transcription factors and abnormal muscle
development in VDR knock-out mice demonstrates the
importance of vitamin D in skeletal muscle development (9).
This suggests that vitamin D deficiency could have important
consequences for muscle metabolism and functioning. Indeed,
vitamin D supplementation during vitamin D deficiency has
been shown to improve musculoskeletal function in
institutionalized elderly by 4-11% within 12 weeks (10).
It has been found in human and mouse primary hepatocyte
cultures that a concentration of 100 nmol·L-1 vitamin D elicits
maximal activation of the VDR (11). The serum vitamin D levels
in rats, around 185 pmol·L-1 (12), are far below this level.
Although it is known that vitamin D supplementation during
vitamin D deficiency enhances muscle function, it remains to be
established what the impact on muscle function is when
circulating vitamin D levels are elevated in non-deficient adult
and old rats. To do so, in this study alfacalcidol, which is a
synthetic calcitriol analogue, is administered to adult and old
rats. We used old rats, as many responses to e.g. electrical
stimulation (13), overload (14) and disuse (14, 15) are reduced.
This might be due to reduced circulating levels of vitamin D.
The aims of this study were to determine the effects of increased
serum 1,25D on muscle contractile properties in old and adult
rats. A decrease in vitamin D concentration observed during
ageing in humans, is the result of a decreased sunlight exposure,
dietary intake, decreased uptake of vitamin D in the food and a
decrease in hydroxylation capacity (16). Because of the last two
factors it was hypothesized that the vitamin D concentration in
the rat is lower in aged rats. Further, we hypothesized that
alfacalcidol treatment would reverse the decline in contractile
properties in old rats.
MATERIAL AND METHODS
Animals
Female Fischer334 x Brown Norway F1 rats were obtained
from Harlan (USA) (n=52). This strain of rats is recommended
by the National Institute of Ageing as the strain of choice for the
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Vitamin D deficiency is associated with muscle weakness. It is unknown, however, how supra-physiological levels of
vitamin D affect skeletal muscle. To investigate the effects of increased serum vitamin D (1,25 (OH)2D3 or 1,25D) levels
on the contractile properties of the medial gastrocnemius muscle, adult and old female Fischer344 x Brown Norway F1
rats were orally treated with vehicle or the vitamin D analogue alfacalcidol for 1 or 6 weeks. Alfacalcidol treatment
resulted in elevated 1,25D serum levels. This was accompanied by hypercalcaemia and a reduction in body mass, the
latter largely attributable to a reduced food intake. However, kidney function, as reflected by normal creatinine serum
levels, as well as heart mass were unaffected. The 17% reduction in maximal isometric force and power was explicable
by a similar loss of muscle mass. The force-frequency relationship of the 6-week-treated old rats was shifted to the left,
but neither the shape of the force-velocity relationship nor the fatigability of the muscle were altered. Supra-
physiological doses of vitamin D were accompanied by significant reductions in body and muscle mass, but not by an
improvement in muscle functioning. Weight loss was largely due to a reduced food intake, while the left shift in the
force-frequency relation may be due to increased 1,25D levels.
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study of ageing processes as it suffers less than other strains
from co-morbidities (17). Rats were housed four to a cage at a
12:12 light dark cycle with food and standard laboratory chow
provided ad libitum. The rats were adult (7 months old), and old
(27,5- or 29-months old) at the end of the treatment period and
divided randomly in 1-week, 6-week, or vehicle treated groups
(Table 1). Rats were orally administered either vehicle or
alfacalcidol (0.1 µg·kg-1) (Chugai Pharmaceutical Co Ltd, Japan)
daily for one week, to study short term effects, or for 5 days
during 6 weeks to study long term effects. This dose has been
shown to inhibit bone resorption and enhance bone formation in
ovariectomized rats treated for 5 weeks (18). Rats were weighed
before vehicle and alfacalcidol administration to determine the
dose. Food and water consumption were monitored in the 6-
week treatment groups. At the end of the treatment period the
contractile properties of the medial gastrocnemius muscle (Gm)
were determined. All experiments were approved by the local
ethics committee of the VU University Amsterdam and conform
to the Dutch Research Council's guide for care and use of
laboratory animals.
Rats were anaesthetized by an initial dose of urethane (0.75
g·kg-1 i.p.). After 10 minutes an additional dose of 0.75 g·kg-1
urethane was given. If the rats still responded to nociceptive
stimuli, supplementary injections of 0.63 g·kg-1 were applied
during the experiment. The Gm of the right leg was dissected while
keeping the proximal origin and the blood supply intact. The femur
was fixed and the distal tendon, with a small part of the calcaneus,
connected to a force transducer. Length changes of the Gm were
controlled by a servomotor connected to the lever arm to which the
force transducer was mounted. The sciatic nerve was cut and
contractions induced by supramaximal electrical stimulation 
(1 mA, pulse width 200 µs), defined as the current above which the
twitch force did not increase further. Subsequently, the muscle was
set at optimal length (Lo), defined as the length at which the active
twitch force was maximal, with a series of twitch contractions 
(1 per minute). Then Lo was fine-adjusted with several tetanic
contractions (150 Hz, 150 ms). Muscle temperature was
maintained at 34-36°C with a water-saturated airflow around the
muscle, which also kept the muscle moistened. Stimulation and
length changes were computer controlled. Force and length signals
were digitized using an AD-converter at a sampling rate of 10 kHz.
At the end of the measurements the Gm was excised, weighed,
stretched to Lo on cork, and frozen in liquid nitrogen.
Protocols
Frequency - force relation
To determine the frequency-force relationship the muscle
was stimulated at the following frequencies in random order: 20,
40, 60, 100, 150 and 250 Hz. The stimulation duration was 150
ms. The time between each contraction was 3 minutes to prevent
the development of fatigue and minimize potentiation.
Force - velocity relation
To determine the force-velocity relation, the muscles were
maximally stimulated with 400-Hz 150-ms trains (19). During
the contractions the muscles were allowed to shorten at a constant
velocity (10, 20, 30, 50, 75, 100 and 125 mm·s-1). Just before the
contraction started, the muscle was passively stretched to a length
0.5-1 mm above Lo. Each contraction started with a short
isometric phase during which the force increased to the level that
could be sustained during the subsequent shortening at the
specific imposed velocity. This ensured that the force was
constant when the muscle passed Lo during shortening (20). Rest
between contractions was 3 minutes.
Fatigue
The fatigue protocol consisted of a series of 20 isometric
contractions (150 Hz; 150 ms; 1 contraction every 500 ms).
Data analysis
For all isometric contractions, net peak force was calculated.
Subsequently, the maximal tetanic force was normalized to
muscle mass. The decrease during the fatigue protocol was
expressed relative to the force of the first tetanic contraction and
for every tetanus during the fatigue protocol, the half relaxation
time (HRT) was calculated. HRT was calculated as the time for
force to decrease from the maximum to 50% of the maximum at
the end of the stimulation.
Blood serum values
Blood was collected from the vena cava inferior after the
contractile properties of the Gm had been determined. Serum
values for 1,25D were measured using a 1,25(OH)2D ELISA kit
(Immunodiagnostic Systems Ltd., Boldon, England). Albumin,
calcium (Ca), creatinine, and inorganic phosphate (Pi) serum
concentrations were determined with a Hitachi Biochemical
Automatic Analyzer 7070 (Hitachi Co., Ltd., Tokyo, Japan).
Statistics
To determine whether there were any statistical differences a
three way ANOVA with as factors age (three levels: 7, 27.5 and
29 months) and duration of alfacalcidol treatment (control, 1 and
6 weeks) was performed on the treatment group and the
corresponding control group (SPSS 17.0). A bonferroni post hoc
test was performed if a significant effect was found. For the
force-frequency relation, force-velocity relation and body mass
as function of treatment duration a two-way ANOVA with
repeated measures on one factor was performed to test for
differences in the whole curve. Differences were considered
significant at p<0.05. Data are presented as mean ±S.D.
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Table 1. Group arrangement, number of animals in each group, treatment and age of the rats used in this experiment. CA: control adult;
A1WA: (alfacalcidol, 1 week, adult), adult rats treated with alfacalcidol for 1 week; A6WO: (alfacalcidol, 6 weeks, old), old rats
treated wih alfacalcidol for 6 weeks; V6WO: (vehicle, 6 weeks, old), old rats treated with vehicle for 6 weeks; A1WO: (alfacalcidol,
1 week, old), old rats treated with alfacalcidol for 1 week; V1WO: (vehicle, 1 week, old) old rats treated with vehicle for 1 week.
RESULTS
Food and water consumption
Food and water intake were monitored daily. The food intake
was 38% lower (p<0.001) in the alfacalcidol than the vehicle
groups. The water intake, on the other hand, was increased by
12.4% (p=0.002) (Fig. 1).
Blood serum levels
Fig. 2 shows that the 1,25D blood serum level was 3-4-fold
higher in both adult (p=0.004) and old rats (p=0.002) treated for
1 week with alfacalcidol compared with vehicle treated rats
resulting in supra-physiological 1,25D levels. 1.25D serum
levels after 1 and 6 week treatment with alfacalcidol in the old
rats did not differ. 1,25D in the old V1WO and V6WO were not
significantly different from those of the adult CA group,
indicating that administration of the vehicle itself had no
significant effect on the 1,25D concentration in the blood.
Hence, there was no age-related reduction in 1,25D levels.
Albumin and creatinine serum levels were similar in all
groups (Table 2). Ca levels were 1.1-1.3 fold elevated in the
alfacalcidol treated groups compared to the corresponding
control groups (p<0.02, Table 2).
Pi serum levels of the old animals were lower than those in
the adult control animals (p<0.001). Alfacalcidol treatment
induced a significant increase in the circulating levels of Pi in the
old rats, irrespective of duration of treatment (p<0.001) (Table 2).
Body and muscle mass
Table 3 shows the body and muscle mass data for the
different groups before and after treatment. The old animals
were heavier than the adult animals (p≤0.001). The vehicle
treatment did not significantly affect body mass. Treatment with
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Fig. 1. Food intake is lower and water
intake is higher in alfacalcidol treated
rats. A) food intake during vehicle and
alfacalcidol treatment in old rats. B)
Water intake during vehicle and
alfacalcidol treatment in old rats. Food
intake was 38% lower and water intake
was 12% higher in alfacalcidol treated
animals compared to vehicle treated
rats. Data is represented as mean ±
S.D.*different from corresponding
control group (p<0.05).
Fig. 2. 1,25D concentration in blood
serum is increased after alfacalcidol
treatment. A) Adult rats orally treated
with alfacalcidol for one week, the
control adult group received no
treatment. B) old rats were treated for
1 and 6 weeks with vehicle or
alfacalcidol. 1,25D blood serum levels
of the alfacalcidol treated animals
were 3-4 fold higher compared to the
corresponding control group. Data is
represented as mean ± S.D.
*different from corresponding control
group (p<0.05).
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Table 2. Mean (±S.D.) of blood serum values at the end of the experimental period. * significantly different from corresponding control
group (p<0.05).
alfacalcidol, on the other hand, caused a 6% reduction in body
mass after 1 week of treatment in adult and old rats (p<0.001),
which progressed to a 22% reduction after 6 weeks of treatment
in the old rats (p<0.001) (Fig. 3).
Ageing did not significantly affect muscle mass. This
applied not only to the Gm (Table 3), but also to the soleus,
plantaris, extensor digitorum longus and tibialis anterior muscles
(data not shown). While 1 week of alfacalcidol treatment did not
cause a significant reduction in Gm mass, it was reduced by
about 17% after 6 weeks of alfacalcidol treatment (p<0.001).
The same was found for the plantaris muscle (p<0.05), but in the
other muscles it did not reach significance. The Gm mass
normalized to body mass was lower (p<0.05) in the old than in
the adult rats. Treatment with alfacalcidol did not reduce this
ratio, indicating that the decrease in body mass was not only due
to a decrease in muscle mass, but also due to a decrease in other
tissue, e.g. fat tissue, to a similar extent (data not shown). The
heart mass increased with age, but when expressed per unit body
mass it decreased (p<0.05; Table 3). The heart mass was not
significantly affected by alfacalcidol, while as a consequence of
the loss of body mass the heart:body mass ratio was increased
after alfacalcidol treatment (p<0.002).
Muscle functional characteristics
Maximal isometric force
Maximal isometric force (Fmax) was lower in the old
vehicle treated rats than the control adult group (p<0.05) (Table
3). Fmax was 19% lower in the old (V1WO) than the control
adult group (p<0.05). Treatment with alfacalcidol for 1 week did
not affect Fmax, but after 6 weeks of treatment Fmax was
reduced by 18% in the old rats. These age- and treatment related
reductions in Fmax were explicable by the decrease in muscle
mass, as the specific force (Fmax normalized by muscle mass)
was similar in all groups (Table 3).
Force-frequency characteristics
The force-frequency curve of the old rats treated with
vehicle for 1 and 6 weeks was shifted to the left compared to the
control adult group, indicating an age effect (p<0.001) (Fig. 4A).
Alfacalcidol treatment for 6 weeks induced a shift in the force-
frequency curve to the left compared to their corresponding
control group (p<0.05) (Fig. 4C).
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Fig. 3. Six weeks alfacalcidol
treatment reduced the body mass of
old rats. Adult rats were orally treated
with vehicle or alfacalcidol for 1
week, and old rats for 1 and 6 weeks
while the adult control group received
no treatment. A) Effects of 1 week
treatment with alfacalcidol. The adult
and old alfacalcidol treated animals
(A1WA and A1WO respectively) had
a significant decrease in body mass
compared to the old rats receiving
vehicle (V1WO) (P<0.03). B) Effects
of 6 week alfacalcidol and vehicle
treatment on old rats. After 6 weeks
alfacalcidol (A6WO) treatment rats
showed a substantial loss of body
mass compared to initial body mass of
the 6 weeks vehicle (V6WO) treated
rats (p=0.001). Data is represented as
mean ±S.D.
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Table 3. Mean (±S.D.) of body mass, gastrocnemius muscle (Gm) mass and maximal tetanic force (Fmax) of the Gm at the end of the
experimental period. * significantly different from CA; ~ significantly different from value before treatment; # significantly different
from other groups; ** significantly different from V6WO (p<0.05).
Force-velocity characteristics
No significant differences were found in the force-velocity
relationships between the groups (data not shown). The Gm of
the oldest animals (V1WO) had lower maximal power outputs
than the adult control group (p<0.001) (data not shown). As a
consequence of the reduction in Fmax after 6 weeks of treatment
with alfacalcidol the maximal power was similarly reduced after
6 weeks of alfacalcidol treatment (p<0.007).
Fatigue
During 20 repeated isometric contractions a linear decrease
to 74% of the initial force was seen in all groups. Concomitantly,
half relaxation time (HRT) time increased during the isometric
repetitions in all groups. The HRT of the non-fatigued non-
treated adult muscles was shorter than that of both old control
groups (p<0.02). There was no significant effect of alfacalcidol
in the HRT (data not shown).
DISCUSSION
The aim of this study was to determine the effects of an
increase in serum 1,25D on the Gm muscle contractile
properties in old and adult rats. We observed that ageing
resulted in a reduction in force and power generating capacity
of the muscle. Administration of the vitamin D analogue
alfacalcidol did increase the 1,25D serum levels but in
contrast to our hypothesis the old rats showed no vitamin D
deficiency. Furthermore, the increased 1,25D serum levels did
not improve the contractile characteristics of the Gm. Rather,
a decrease in maximal force and power generating capacity
and a left-shift of the force frequency relationship of the Gm
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Fig. 4. Influence of age and
alfacalcidol treatment on the force-
frequency relationship. A) Force-
frequency relation is shifted to the left
in old animals, indicating an age
effect. Old rats were treated with
vehicle for 1 or 6 weeks (V1WO and
V6WO respectively), the control adult
(CA) group received no treatment. 
* V6WO and V1WO different from
CA (p<0.001). B) 1 week treatment
with alfacalcidol in old animals did
not effect the force frequency
relationship. Old rats were treated for
1 week with vehicle or alfacalcidol
(V1WO and A1WO respectively). C)
6 weeks alfacalcidol treatment in old
rats resulted in a left-shift in the force
frequency relationship. Old rats were
treated with alfacalcidol or vehicle for
6 weeks (A6WO and V6WO
respectively). Lower frequencies
resulted in a higher percentage of the
maximal force in the alfacalcidol
treated rats compared to the old rats
treated with vehicle during 6 weeks.
Data is represented as mean ± S.D.
* A6WO different from corresponding
control group (V6WO) (p<0.05).
in old rats was found. Thus, while administration of
alfacalcidol and other vitamin D analogues has been proven
beneficial for muscle function in conditions of vitamin D
deficiency (10, 21, 22), our data indicate that elevated vitamin
D levels may negatively affect muscle function. This suggest
that the effect of vitamin D on muscle and the whole body may
have a U-shape where below and above normal physiological
levels circulating vitamin D or their analogues have a
negative, rather than a beneficial effect.
Effects of ageing: serum levels and muscle contractile
properties
Albumin, calcium and creatinine levels were not affected by
ageing in our study, but the inorganic phosphate serum
concentrations in serum were significantly lower in the old than
the adult animals.
During ageing in humans levels of 1,25D in blood serum
decrease (23, 24), but we did not find lower 1,25D levels in our
old rats. It is possible that part of the discrepancy between the
decrease in vitamin D during ageing in men and the unaltered
levels we found in rats is explicable by an age-related reduction
in sun-exposure and dietary intake in humans (25), whereas
neither the adult nor the old rats were exposed to sunshine and
rats were fed the same diet at all ages. In contrast to humans, the
vitamin D levels in rats may only depend on nutrition, the
quality of which was maintained in our experimental setting. In
line with previous observations, we observed a significant
slowing of relaxation, and decline in force (14) and power
generating capacity, as observed in old mice (26) with ageing.
These changes were largely due to a reduction in specific tension
as muscle mass was maintained, similar to what has been
observed previously (14, 27).
Six weeks of alfacalcidol treatment did cause a left shift in
the force frequency relation in old rats. If, as a result of
atrophy sarcoplasmic reticulum proteins were less reduced
than contractile proteins, this might contribute to the higher
forces observed at low stimulation frequencies, because of a
possible relatively higher Ca2+ release. If atrophy would lead
to more reduction in sarcoplasmic reticulum proteins, this
might increase half relaxation times, which was not found in
this study. Further support for the absence of changes in the
rate in relaxation comes from the unaltered force-velocity
relation, suggesting that there is no major change in cross-
bridge kinetics, and hence fibre type composition, after
alfacalcidol treatment. Another possibility is that the Ca2+
sensitivity of the regulatory proteins on the thin filaments was
increased, a situation which has for instance been observed in
diaphragm fibres from patients with chronic obstructive
pulmonary disease (28). Finally, the release of Ca2+ by the
sarcoplasmic reticulum might be enhanced at low stimulation
frequencies and/or the intracellular Ca2+ concentration might
already be slightly elevated after treatment with alfacalcidol.
Indeed, vitamin D has been shown to change the intracellular
Ca2+ concentration via both non-genomic (29) and genomic
actions (30). However, because we have not used pair-feeding
in this study, we cannot exclude an influence of reduced food
intake with resultant loss of body mass.
Effects of alfacalcidol treatment: short-term and long-term effects
on blood serum levels, animal characteristics (physiology) and
muscle properties
The levels of circulating vitamin D we observed in the
control adult and old rats were between 45 and 100 pmol·L-1.
This concentration has been found to activate only about 3% of
the VDR in mouse and human hepatocytes (11). Although the
dose response curve for rat is not known it can be assumed that
the activation of the VDR would be in the same range in the rat.
By elevating the vitamin D levels with alfacalcidol treatment one
would expect, based on the dose response curve of Reschly et al.
(11), that the activation of the VDR would increase to
approximately 12-20% at the levels of vitamin D we observed.
Such an increase may have a significant impact on skeletal
muscle structure and function as VDR knock-out mice, for
instance, show abnormal muscle development (9).
While the treatment with alfacalcidol did not significantly
affect the fatigue resistance of the muscle, it did cause a
significant reduction in the force generating capacity of both
adult and old muscles. This muscle weakness was solely due to
a concomitant loss of muscle mass, while the force generating
capacity, or force per unit muscle mass, of the remaining
muscle tissue was unaffected. Not only Gm mass, but also the
mass of the extensor digitorium longus, soleus, plantaris and
tibialis anterior was reduced, suggesting that muscle wasting
occurred irrespective of the fibre type composition of the
muscle. There was also a significant loss of body mass. The
fact that the muscle mass: body mass ratios remained constant
indicates that there was a proportional loss of fat and lean body
mass. The heart mass, however, remained unaffected. The loss
of body mass was largely due to a reduced food intake during
the alfacalcidol administration. The lower food intake is
probably responsible for the decrease in muscle and body mass
and maximal force, however, the qualitative result, the left shift
in the force-frequency relation, may be due to increased
vitamin D levels.
Alfacalcidol treatment resulted in elevated serum levels
1,25D, which may have facilitates the Ca2+ absorption from the
intestine and reabsorption in the kidney (31). It is therefore not
surprising that we found elevated Ca2+ concentrations in the
serum of alfacalcidol-treated rats. The transport protein
albumin has a high affinity for Ca2+ and up to 40% is bound and
inactive, depending upon albumin concentration and pH (32).
A decrease in albumin concentration can therefore lead to an
increase in the free Ca2+ concentration in the blood. However,
the albumin blood concentration was not decreased in the
alfacalcidol groups compared to the vehicle and control
groups. A more plausible explanation for the hypercalcemia is
the increased free 1,25D serum not bound to vitamin D-binding
protein (33, 34).
Further evidence for problems when vitamin D levels are
elevated is the increased fluid intake in alfacalcidol-treated
animals. Nevertheless, the blood analysis showed that the
creatinine concentration was not significantly changed
indicating that the kidney function was normal. Interestingly,
also the heart was spared from the toxic effect, in contrast to the
significant loss of skeletal muscle tissue.
Supplementation with active forms of vitamin D such as
calcitriol and alfacalcidol have been associated with a higher
risk of hypercalcaemia compared to native vitamin D (35).
Symptoms of vitamin D poisoning, which work via
hypercalcaemia, include among other things diarrhoea,
lethargy, weakness, polyuria, polydipsia and anorexia. In this
study we observed polydipsia, hypercalcaemia and anorexia,
which support the idea that the animals which received
alfacalcidol were treated with a too high dose of alfacalcidol
leading to a deficit in food intake. The mechanisms underlying
the adverse effects of alfacalcidol treatment warrant further
investigation. Future research should test whether the adverse
effects of supraphysiological levels of vitamin D can be
reverted by immediate cessation of alfacalcidol
administration, by VDR antagonist supplementation or by
nutritional administration of Ca2+ to normalize its blood serum
concentration.
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Consequence of treatment with alfacalcidol for elderly people
health
Supraphysiological circulating levels of vitamin D are
accompanied by significant reductions in body and muscle mass,
largely due to a reduced food intake. This indicates that food
intake and body mass should be carefully monitored when
treating people with vitamin D analogues. Further, vitamin D
supplementation did not lead to apparent improvement in muscle
functioning. The quantitative results of this study such as the
decrease in muscle and body mass and maximal force production
are probably related to lower food intake, whereas the qualitative
results, the left shift in the force-frequency relation, may be
related to increased vitamin D levels.
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